Early access schemes enable patients in exceptional need to access therapies that are not yet available through their health system. These schemes were not designed for single-administration therapies. In a report published today, OHE authors present key considerations for developing early access schemes for single-administration therapies.
In a commentary piece recently published in Applied Health Economics and Health Policy, OHE authors discuss how the misalignment in interpretations of the term ‘unmet medical need’ by different stakeholders has led to insufficient incentives for development in areas with urgent, genuine need, and propose a new framework for developing a more consistent understanding of UMN that will increase innovation.
In a recently published report, we explore the financial sustainability of gene therapies and highlight the factors that are likely to influence the financial sustainability of this important medical technology.
Case studies explored more and less successful practices when delivering healthcare across four priority areas (screening, disease management and standardised patient pathways, rational use of medicines and healthcare associated infections). Results were used to simulate cost-savings and patient outcomes that could potentially be realised with improvements in efficiency across the European Union of 27 countries and the United Kingdom.
The inclusion of productivity value in the appraisal of health technologies is a subject of ongoing debate. In this blog, we discuss the potential impact of not considering productivity costs in the evaluation of vaccination programmes in the UK.
In light of concerns that not all medicines for ultra-rare (also known as ultra-orphan) conditions are appraised under the same NICE process, a new OHE Consulting Report discusses the distinct ethical and economic challenges faced by medicines for ultra-rare conditions, with particular reference to the challenges of HTA in the UK. A failure to consistently consider all ultra-rare disease medicines under the HST process could lead to inequalities in access and health outcomes for patients with ultra-rare conditions.
A new OHE Consulting Report describes the current status of real-world data in Japan, including core legislation and governance arrangements. The authors sought to understand how real-world data is accessed or generated and used to produce or generate real-world evidence, and to see whether use is aligned with international standards.
Although the quality of palliative care in England and the wider UK is regarded as excellent, many patients receiving palliative care die in pain. This new study estimates that more than 5,000 patients would die in pain every year even under the ‘best practice’ palliative care such as that provided in hospices.
At the recent ISPOR Annual Conference, OHE’s Chief Executive, Professor Graham Cookson announced a new programme of work on Value 2.0: Assessing the Value of US Healthcare to be funded by PhRMA. Graham was joined by the Innovation and Value Institute’s Executive Director Jenn Bright, and Harvard Medical School Professor Bapu Jena.